These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10967627)

  • 21. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of clinical and surgical-pathological staging in IIIA non-small cell lung cancer patients.
    Muehling B; Wehrmann C; Oberhuber A; Schelzig H; Barth T; Orend KH
    Ann Surg Oncol; 2012 Jan; 19(1):89-93. PubMed ID: 21755379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer.
    Changlai SP; Tsai SC; Chou MC; Ho YJ; Kao CH
    Oncol Rep; 2001; 8(2):337-9. PubMed ID: 11182051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice.
    Sachs S; Bilfinger TV
    Chest; 2005 Aug; 128(2):698-703. PubMed ID: 16100156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients.
    Knight SJ; Nathan DP; Siston AK; Kattan MW; Elstein AS; Collela KM; Wolf MS; Slimack NS; Bennett CL; Golub RM
    Clin Prostate Cancer; 2002 Sep; 1(2):105-14. PubMed ID: 15046701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction. Non-small cell lung cancer: some important questions to be solved.
    Mornex F
    Semin Radiat Oncol; 2004 Oct; 14(4):277-9. PubMed ID: 15558500
    [No Abstract]   [Full Text] [Related]  

  • 27. Non-small cell lung cancer: staging at whole-body PET.
    Podoloff DA
    Radiology; 2000 Dec; 217(3):918-9. PubMed ID: 11110966
    [No Abstract]   [Full Text] [Related]  

  • 28. Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment.
    Tan L; Solomon B
    PET Clin; 2018 Jan; 13(1):33-42. PubMed ID: 29157384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The willingness to pay for positron emission tomography (PET): evaluation of suspected lung cancer using contingent valuation.
    Papatheofanis FJ
    Q J Nucl Med; 2000 Jun; 44(2):191-6. PubMed ID: 10967628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health state utilities in non-small cell lung cancer: An international study.
    Nafees B; Lloyd AJ; Dewilde S; Rajan N; Lorenzo M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e195-e203. PubMed ID: 26990789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health state utilities in patients with advanced non-small-cell lung cancer in China.
    Shen Y; Wu B; Wang X; Zhu J
    J Comp Eff Res; 2018 May; 7(5):443-452. PubMed ID: 29775084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decision based on big data research for non-small cell lung cancer in medical artificial system in developing country.
    Wu J; Tan Y; Chen Z; Zhao M
    Comput Methods Programs Biomed; 2018 Jun; 159():87-101. PubMed ID: 29650322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timeliness across the continuum of care in veterans with lung cancer.
    Powell AA; Schultz EM; Ordin DL; Enderle MA; Graham BA; Partin MR; Gould MK
    J Thorac Oncol; 2008 Sep; 3(9):951-7. PubMed ID: 18758295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea.
    Kim EJ; Ock M; Kim KP; Jung NH; Lee HJ; Kim SH; Jo MW
    BMC Cancer; 2018 Nov; 18(1):1081. PubMed ID: 30409116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient participation in clinical decision-making for treatment of T3 laryngeal cancer: a comparison of state and process utilities.
    van der Donk J; Levendag PC; Kuijpers AJ; Roest FH; Habbema JD; Meeuwis CA; Schmitz PI
    J Clin Oncol; 1995 Sep; 13(9):2369-78. PubMed ID: 7666096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET scans approved for detecting metastatic non-small-cell lung cancer.
    McCann J
    J Natl Cancer Inst; 1998 Jan; 90(2):94-6. PubMed ID: 9450567
    [No Abstract]   [Full Text] [Related]  

  • 37. Rapid approximation of confidence intervals for Markov process decision models: applications in decision support systems.
    Cher DJ; Lenert LA
    J Am Med Inform Assoc; 1997; 4(4):301-12. PubMed ID: 9223036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Requirements for clinical PET: comparisons within Europe.
    Bedford M; Maisey MN
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):208-21. PubMed ID: 15129703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Markov models in medical decision making: a practical guide.
    Sonnenberg FA; Beck JR
    Med Decis Making; 1993; 13(4):322-38. PubMed ID: 8246705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer.
    Révész D; Engelhardt EG; Tamminga JJ; Schramel FMNH; Onwuteaka-Philipsen BD; van de Garde EMW; Steyerberg EW; de Vet HCW; Coupé VMH
    J Cancer Educ; 2020 Apr; 35(2):345-351. PubMed ID: 30685832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.